Clinical Trials Directory

Trials / Conditions / Plasmablastic Lymphoma

Plasmablastic Lymphoma

12 registered clinical trials studyying Plasmablastic Lymphoma — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496
The First Affiliated Hospital with Nanjing Medical UniversityPhase 1
RecruitingStudy on Plasmablastic Lymphoma Patients
NCT06781359
Fondazione Italiana Linfomi - ETS—
RecruitingPomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
NCT05389423
National Cancer Institute (NCI)Phase 1
RecruitingCollecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
AIDS Malignancy Consortium—
RecruitingStudy of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Schrödinger, Inc.Phase 1
RecruitingStudy to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
NCT04915248
Fondazione Italiana Linfomi - ETSPhase 2
RecruitingA Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
NCT04139304
AIDS Malignancy ConsortiumEARLY_Phase 1
Active Not RecruitingNivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho
NCT03038672
National Cancer Institute (NCI)Phase 2
Active Not RecruitingGene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Trans
NCT02797470
AIDS Malignancy ConsortiumPhase 1 / Phase 2
UnknownCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
NCT02481310
Northwestern UniversityPhase 1 / Phase 2
CompletedVorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-C
NCT01193842
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedPhase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse L
NCT01092182
National Cancer Institute (NCI)Phase 2